[Seroprevalence of hepatitis C in human immunodeficiency virus infected patients].
Prevalence of antibodies against hepatitis C virus (HCV) was evaluated using Ortho and Abbott HCV Elisa assays and the Abbott EIA Neutralization assay in 150 human immunodeficiency virus (HIV)-seropositive patients and compared with the prevalence of hepatitis B virus (HBV) and hepatitis D virus (HDV) markers. Overall prevalence of hepatitis C virus antibodies was 29.3%; significant variations were seen across human immunodeficiency virus risk factor subgroups: prevalence was 10.2% in homosexual men, 12.0% in bisexual men, 73.5% in intravenous drug users, 13.3% in blood transfusion recipients, and 16.6% in frequent travellers. Seroprevalence was higher in the 20 to 40 year-old age group and in patients stage II or III according to the Center for Disease Control classification. Prevalence of hepatitis B virus and hepatitis D virus markers (75.7% and 17.5% respectively) was analyzed according to hepatitis C virus marker status; patients with HBcAb were more likely to have antibodies against hepatitis C virus than their HBcAb-negative counterparts. Further studies are needed to investigate the influence of coexposure to human immunodeficiency virus and hepatitis C virus on liver lesions. Data from this study show that coinfection or coexposure is common.
Ranger
S
S
Service de Bactériologie-Virologie, CHU Dupuytren, Limoges, France.
Aussel
L
L
Weinbreck
P
P
Loustaud
V
V
Rogues
A M
AM
Mounier
M
M
Delpeyroux
C
C
Denis
F
F
D000328:Adult; D000367:Age Factors; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006508:Hepatitis Antibodies / Q000032:analysis*; D006509:Hepatitis B / Q000150:complications / Q000276:immunology; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology* / Q000276:immunology; D003699:Hepatitis D / Q000150:complications / Q000276:immunology; D006801:Humans; D008297:Male; D015995:Prevalence; D012307:Risk Factors
D006508:Hepatitis Antibodies
Séroprévalence de l'hépatite C chez les sujets contaminés par le virus de l'immunodéficience humaine.